A powerful whole
organism model for accelerating ageing research
A positive control for longevity research
Ageing is accompanied by cellular damage that contributes to various age-related disorders. The mTOR signalling network plays a crucial role in regulating ageing and associated diseases like metabolic disorders, neurodegeneration, and cancer. Rapamycin, an mTOR inhibitor, has demonstrated the ability to slow ageing and extend healthspan and lifespan across different model organisms, and shows promise in humans
Despite its potential, Rapamycin’s effectiveness in extending lifespan has shown inconsistent results in C. elegans studies. Its commercial use to slow ageing in humans has been impeded by its known toxicity against β-cells, and efforts to develop rapamycin analogs (rapalogs) and similar molecules with a lower toxicity profile have been slowed-down by the lengthy duration of ageing studies in mammalian models.
Magnitude Biosciences developed a novel assay using our automated WormGazerTM technology to consistently demonstrate positive effects of Rapamycin on worm movement and improved healthspan in aged worms. This robust assay provides a decisive method to investigate new mTOR inhibitors and other novel longevity compounds, using Rapamycin as a positive control.
Our assay evaluates the effects of compounds on age-related mobility decline and healthspan extension compared to Rapamycin. Using metabolically-inactive bacteria and our automated imaging system, we monitor worm movement 24 hours a day over 14 days to quantify healthspan extension.
Collaborate with Magnitude Biosciences to accelerate your research on compounds to slow ageing. Our Rapamycin assay offers a streamlined approach to assess compound efficacy and compare results to the gold standard.
Contact us to explore how our Rapamycin assay can advance your research on longevity therapeutics and support drug discovery efforts.
SERVICES
Contract lab services for your research area
Sign up to our newsletter today, to get access to the latest company and industry news